These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7911332)

  • 1. Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database.
    Mant A; Whicker SD; McManus P; Birkett DJ; Edmonds D; Dumbrell D
    Aust J Public Health; 1993 Dec; 17(4):345-9. PubMed ID: 7911332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?
    Gisev N; Pearson SA; Karanges EA; Larance B; Buckley NA; Larney S; Dobbins T; Blanch B; Degenhardt L
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):550-555. PubMed ID: 29047196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-year trends in benzodiazepine dispensing in the Australian population.
    Islam MM; Conigrave KM; Day CA; Nguyen Y; Haber PS
    Intern Med J; 2014 Jan; 44(1):57-64. PubMed ID: 24450521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent trends in the prescribing of cholesterol lowering drugs in Australia. A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee.
    Henry DA; Cully LR; Grigson T; Lee C
    Med J Aust; 1991 Sep; 155(5):332-6. PubMed ID: 1895979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada.
    Tett SE; Sketris I; Cooke C; van Zanten SV; Barozzi N
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):735-43. PubMed ID: 23559528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychoactive drug prescribing in the Tasmanian community.
    Jacobson GA; Friesen WT; Peterson GM; Rumble RH; Polack AE
    Med J Aust; 1992 Jul; 157(1):20-4. PubMed ID: 1353603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiolytic, hypnotic and sedative medication use in Australia.
    Hollingworth SA; Siskind DJ
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):280-8. PubMed ID: 20073039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study.
    Sidorchuk A; Isomura K; Molero Y; Hellner C; Lichtenstein P; Chang Z; Franck J; Fernández de la Cruz L; Mataix-Cols D
    PLoS Med; 2018 Aug; 15(8):e1002635. PubMed ID: 30086134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the market uptake of new drugs following listing for subsidy in Australia. A report from the Drug Utilisation Subcommittee of the Australian Pharmaceutical Benefits Advisory Committee.
    Birkett DJ; McManus P
    Br J Clin Pharmacol; 1995 Oct; 40(4):407-10. PubMed ID: 8554945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezetimibe: Use, costs, and adverse events in Australia.
    Hollingworth SA; Ostino R; David MC; Martin JH; Tett SE
    Cardiovasc Ther; 2017 Feb; 35(1):40-46. PubMed ID: 27860332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia.
    Degenhardt L; Roxburgh A; van Beek I; Hall WD; Robinson MK; Ross J; Mant A
    Drug Alcohol Rev; 2008 Mar; 27(2):145-51. PubMed ID: 18264874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription opioid analgesics for pain management in Australia: 20 years of dispensing.
    Islam MM; McRae IS; Mazumdar S; Taplin S; McKetin R
    Intern Med J; 2016 Aug; 46(8):955-63. PubMed ID: 26602489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of benzodiazepine and related drug use in Nova Scotia and Australia.
    Smith AJ; Sketris I; Cooke C; Gardner D; Kisely S; Tett SE
    Can J Psychiatry; 2008 Aug; 53(8):545-52. PubMed ID: 18801216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of mycophenolate use in Australia and Northern Europe, and the impact on the pharmaceutical benefits scheme.
    Staatz CE; Smith AJ; Tett SE
    Pharmacoepidemiol Drug Saf; 2009 May; 18(5):386-92. PubMed ID: 19253908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dispensing Patterns of Anxiolytics and Sedative-Hypnotics: A Feasibility Study Comparing Datasets from a Developed and a Developing Country (Australia and South Africa).
    Kairuz T; Truter I; Rossato L; Pudmenzky A
    Curr Drug Saf; 2017; 12(1):57-61. PubMed ID: 28067180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of benzodiazepines in Chile during 1982-1986.
    Ruiz I; Offermanns J; Fuentes P; Castillo M
    Eur J Clin Pharmacol; 1989; 37(2):139-43. PubMed ID: 2571504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiles of antibacterial drug use in Australia and trends from 1987 to 1989. A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee.
    Birkett DJ; Mitchell AS; Godeck A; Grigson T; Cully R; Lee C
    Med J Aust; 1991 Sep; 155(6):410-5. PubMed ID: 1921794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of injecting drug users in Sydney, Melbourne and Brisbane to rising benzodiazepine use in Australia 2000 to 2006.
    Smith A; Tett S; Hall W
    Aust N Z J Public Health; 2010 Jun; 34(3):315-9. PubMed ID: 20618276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 5-year follow-up study of users of benzodiazepine: starting with diazepam versus oxazepam.
    Tvete IF; Bjørner T; Skomedal T
    Br J Gen Pract; 2016 Apr; 66(645):e241-7. PubMed ID: 26965028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in anticonvulsant prescribing for Australian children: implications for Quality Use of Medicines.
    Cohen SA; Lawson JA; Graudins LV; Pearson SA; Gazarian M
    J Paediatr Child Health; 2012 Jun; 48(6):490-5. PubMed ID: 22050665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.